Initial Therapy Matters for Clostridioides difficile – Get it Right the First Time
C. difficile Clinical Commentary
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.Start Activity
• Discuss the selection of antimicrobials considerate of their spectrum and impact on gut microbiota
• Evaluate the role of monoclonal antibodies in the treatment and prevention of recurrent C. difficile infection
• Describe clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Optimize diagnostic methods to improve recognition of C. difficile infection both in the hospital and community setting
Assistant Professor of Internal Medicine
Department of Internal Medicine
Rush University Medical Center
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.By providing your ABIM Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system.